NASDAQ: ORMP ORAMED PHARMACEUTICALS INC. 10-Q

Oramed pivots from pharma R&D to medical-tech operator; spins out oral insulin IP to Lifeward

Filed May 19, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 15, 2025 · ~2 min read

5 material changes detected in this filing.

Create a free account to read the full summary — it takes 30 seconds.

Partner

Trade ORMP commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

View original filing on SEC.gov

Generated by AI · May 26, 2026 4:38 PM